Companies: 10,795·Total market cap: $144.5T
EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals, Inc.

EPRSQOTCHealthcare
$0.00
$-0.00(-99.00%)
Market Cap$1571
P/E Ratio
52W High
52W Low

EPIRUS Biopharmaceuticals, Inc. (EPRSQ) Revenue

Annual & quarterly revenue history · segment & region breakdown

EPRSQ · revenue · updated Jun 9, 2026

Core revenue metrics

EPIRUS Biopharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
73 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · EPIRUS Biopharmaceuticals, Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
EPRSQ revenue by year · EPRSQ revenue history · EPRSQ annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income EPIRUS Biopharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

EPIRUS Biopharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from EPIRUS Biopharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

EPRSQ revenue · 4 questions

EPRSQ's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

EPRSQ revenueEPRSQ annual revenuewhat is EPRSQ revenueEPRSQ TTM revenue

Source: FMP · EPIRUS Biopharmaceuticals, Inc. SEC filings · GAAP · EPIRUS Biopharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026